Platelet Survival and Function in Animals with Prosthetic Mitral Valve: The Effect of Nafazatrom

Summary

Thromboembolism remains a serious problem in patients with prosthetic heart valves. Previous studies documented a number of platelet abnormalities in such patients and correlated the occurrence of thromboembolic complications with short platelet survival. We have studied platelet survival and platelet aggregation in eight goats fitted with prosthetic mitral valves and repeated the studies following treatment with nafazatrom, a potent antithrombotic agent. Eleven survival studies in eight animals showed a platelet survival not significantly different from control (6.52 ± 0.72 vs. 6.94 ± 0.81 days). Following seven to ten days of oral drug administration, platelet survival in the test animals was 7.34 ± 0.96 days, significantly longer than pretreatment results (p <0.01). Animals with the shortest pretreatment platelet survival achieved substantial prolongation of platelet life span following drug treatment. The drug caused no change in ex vivo platelet aggregation.

Keywords

Platelet survival - Platelet aggregation - Prosthetic heart valves - Nafazatrom

• References

• 1 Turpie AG G, de Boer AC, Genton E. Platelet consumption in cardiovascular disease. Semin Thromb Haemostas 1982; 8: 161-185
• 2 Weily HS, Genton E. Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy Circulation 1970; 42: 967-972
• 3 Weily HS, Steele PP, Davies H, Pappas G, Genton E. Platelet survival in patients with substitute heart valves. N Engl J Med 1974; 290: 534-537
• 4 Steele P, Rainwater J, Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves. Circulation 1979; 60: 910-913
• 5 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
• 6 Sullivan JM, Harker DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement: a preliminary report. N Engl J Med 1968; 279: 576-580
• 7 Seuter F, Busse WD, Meng K, Hoffmeister F, Moller E, Horstmann H. The antithrombotic activity of Bay g 6575. Arzneim Forsch 1979; 29: 54-59
• 8 Buchanan MR, Blajchman M, Hirsh J. Inhibition of arterial thrombosis and platelet function by nafazatrom. Thromb Res 1982; 28: 157-170
• 9 Wisman CB, Pierce WS, Donachy JH, Pae WE, Myers JL, Prophet GA. A polyurethane trileaflet cardiac valve prosthesis: In vitro and in vivo studies. Trans Am Soc Artif Intern Organs 1982; 23: 164-168
• 10 Schmidt KG, Rasmussen JW. Preparation of platelet suspensions from whole blood in buffer. Description of a method which gives a large platelet yield Scand J Haematol 1979; 23: 88-96
• 11 Riba AL, Thakur ML, Gottschalk A, Andriole VT, Zaret BL. Imaging experimental infective endocarditis with Indium-111 labeled blood cellular components. Circulation 1978; 59: 336-343
• 12 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-5363
• 13 Knudson DL, Buckley SM. Invertebrate cell culture methods for the study of invertebrate-associated animal viruses. In: Methods in Virology. Maramorsch K, Kaprowski H. (eds.) Academic Press; New York: 1977. p 345
• 14 Scheffell U, McIntyre PA, Evatt B, Dvomicky Jr JA, Natarayan TK, Bolling DR, Murphy EH. Evaluation of Indium-111 as a new high photon yield gamma emitting “physiological7#x201D; platelet label. The Johns Hopkins Med J 1977; 140: 285-293
• 15 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
• 16 Zar JH. Ed Bionomial distribution. In: Biostatistical Analysis. Englewood Cliffs, NJ: Prentice Hall; 1974. p 292
• 17 Seuter F, Busse WD. Mechanisms of action of nafazatrom. Thromb Res 1983; Supp (Suppl. 04) 75-80
• 18 Buchanan MR, Blajchman M, Hirsh J. Inhibition of arterial thrombosis and platelet function by nafazatrom. Thromb Res 1982; 28: 157-170
• 19 Vermylen J, Chamone DA F, Verstraete M. Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound. Lancet 1979; 1: 518-520
• 20 Hermann KS, Seuter F. Nafazatrom delays platelet aggregation induced with a fluorescent dye in hamster cheek pouch. Naunyn-Schmiedeberg’s Arch Pharmacol 1982; Suppl (Suppl. 319) 130-133
• 21 Carreras LO, Chamone DA F, Klerckx P, Vermylen J. Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575 Thromb Res 1980; 19: 663-670
• 22 McIntyre DE, Salzman EW. Effects of Bay g 6575 on platelets and on vascular PGI2 production. Thromb Haemostas 1981; 46: 19 (Abstr.)
• 23 Chamone DA F, Van Damme B, Carreras LO, Vermylen J. Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g 6575. Hemostasis 1981; 10: 297-303